TY - JOUR
T1 - The Personal Antipsychotic Choice Index
AU - Van Dijk, Floor
AU - De Wit, Iris
AU - Blankers, Matthijs
AU - Sommer, Iris
AU - De Haan, Lieuwe
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Introduction We present an online decision aid to involve patients with a psychotic disorder in shared decision-making concerning the selection of antipsychotic medication. Method Patients selected effectiveness and adverse effects criteria from the Subject's Response to Antipsychotics-34 questionnaire. Numerical data from meta-analyses, clinical trial data, receptor affinities and expert opinions were used to rank antipsychotics on each criterion. When using the the tool, patients indicate on a 5-point Likert scale how they value each (adverse) effect. The Likert scale values are combined in an algorithm with the rank orders of antipsychotics to create a personalized ranking. Results Criteria used were: effectiveness concerning psychotic, depressive and cognitive symptoms, weight gain, sexual dysfunction, drowsiness, hypersomnia, extrapyramidal symptoms, anticholinergic adverse effects, hypersalivation, nausea, dizziness, energy loss, blunted affect/less need for companionship. High-level evidence was available for ranking weight gain, sexual dysfunction, menstrual disorders, extrapyramidal symptoms and effectiveness on psychotic symptoms. We used lower level evidence ranking the remaining criteria. Discussion A transparent procedure has resulted in an updateable tool to produce individual ranking of antipsychotics based on the patients' input.
AB - Introduction We present an online decision aid to involve patients with a psychotic disorder in shared decision-making concerning the selection of antipsychotic medication. Method Patients selected effectiveness and adverse effects criteria from the Subject's Response to Antipsychotics-34 questionnaire. Numerical data from meta-analyses, clinical trial data, receptor affinities and expert opinions were used to rank antipsychotics on each criterion. When using the the tool, patients indicate on a 5-point Likert scale how they value each (adverse) effect. The Likert scale values are combined in an algorithm with the rank orders of antipsychotics to create a personalized ranking. Results Criteria used were: effectiveness concerning psychotic, depressive and cognitive symptoms, weight gain, sexual dysfunction, drowsiness, hypersomnia, extrapyramidal symptoms, anticholinergic adverse effects, hypersalivation, nausea, dizziness, energy loss, blunted affect/less need for companionship. High-level evidence was available for ranking weight gain, sexual dysfunction, menstrual disorders, extrapyramidal symptoms and effectiveness on psychotic symptoms. We used lower level evidence ranking the remaining criteria. Discussion A transparent procedure has resulted in an updateable tool to produce individual ranking of antipsychotics based on the patients' input.
KW - adherence
KW - antipsychotics
KW - psychosis
KW - shared decision making
KW - web tool
UR - http://www.scopus.com/inward/record.url?scp=85027990199&partnerID=8YFLogxK
U2 - 10.1055/s-0043-116854
DO - 10.1055/s-0043-116854
M3 - Article
C2 - 28810270
AN - SCOPUS:85027990199
SN - 0176-3679
VL - 51
SP - 89
EP - 99
JO - Pharmacopsychiatry
JF - Pharmacopsychiatry
IS - 3
ER -